Trial reportJournal for immunotherapy of cancer2021
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Trial report in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03816553 (SHR-1210, a Novel Anti-pd-1 Antibody, in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SHR-1210, a Novel Anti-pd-1 Antibody, in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: a Single-arm, Open Label, Multi-center, Phase II Study
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review.Frontiers in immunology · 2024Pooled it
- Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer.BMC medicine · 2025Trial
- Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Clinical and nutritional-inflammatory biomarkers-based nomogram predicts survival in recurrent or metastatic cervical cancer treated with immune checkpoint inhibitors.Annals of medicine · 2026Article
- Identification of candidate variants in plasma associated with early versus late disease progression under anti-PD-1 therapy in metastatic NSCLC.Translational lung cancer research · 2026Article
- Paired genomic profiling of primary tumor and lymph-node metastases identifies candidate prognostic features in penile squamous cell carcinoma.The oncologist · 2026Article
- Clinicopathological characterization of cervical squamous cell carcinoma withOncology letters · 2026Article
- Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer.The oncologist · 2026Article
- Mechanism of Xiao-ai-fei Honey Ointment, a Traditional Uyghur Multi-Ingredient Medicinal Preparation, Against Cervical Cancer Based on Network Pharmacology and In Vitro Evaluation of Anti-Cancer Activity.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study).Gastroenterology report · 2026Article
- Clinicopathologic and molecular characterization of uterine and ovarian mixed yolk sac tumor and carcinoma/carcinosarcoma: implications for somatic derivation and therapeutics.Virchows Archiv : an international journal of pathology · 2026Article
- Tumor Genomic Profiles Associated with Clinical Benefit from Immune Checkpoint Inhibitor Therapy - An Exploratory Analysis of the INFINITY Precision Oncology Registry.OncoTargets and therapy · 2026Article
- PIK3CA mutation-induced immune microenvironment remodeling sensitizes cervical cancer to immunotherapy.Frontiers in immunology · 2026Article
- Tumor apparent diffusion coefficient as a predictive marker for PD-1 inhibitor outcome in advanced cervical cancer: a retrospective study.Frontiers in oncology · 2026Article
- The Oncologist, 2025, Vol, XX, Issue XX Predictive role of ARID1A and B2M mutations and the antigen presentation pathway in the efficacy of definitive chemoradiotherapy for cervical cancer.The oncologist · 2025Article
- Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphoma.Cancer cell international · 2025Article
- The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?Frontiers in immunology · 2025Review
- Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report.Frontiers in immunology · 2025Article
- The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer.Cancer medicine · 2024Article
- Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial.Cancer communications (London, England) · 2024Article
Corrections and comments
- Erratum issuedCorrection:2022
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Camrelizumab Plus Apatinib in Patients with Advanced Cervical Cancer trial was a single-arm, phase II study that showed promising activity of the programmed death-1 (PD-1) inhibitor camrelizumab plus the vascular endothelial growth factor receptor-2 inhibitor apatinib in patients with advanced cervical cancer. However, the predictive biomarkers for treatment outcomes are unknown. In this study, we aimed to identify potential predictors of treatment response in PD-1 inhibitor combination therapy.
methodsGenomic profiling was performed on patients with available biopsy or surgical samples by targeted next-generation sequencing of 425 cancer-related genes in this preplanned, secondary analysis. Somatic alterations, including all non-synonymous mutations, and tumor mutational burden (TMB) were assessed for their predictive values in objective response rate, progression-free survival (PFS), and overall survival (OS).
resultsA subset of 32 patients was included in this analysis. Top altered genes included
conclusionsWe uncovered that genetic alterations in TRIAL REGISTRATION NUMBER: NCT03816553.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.